The Peter Attia Drive - November 16, 2020


#137 - Paul Offit, M.D.: An expert perspective on COVID-19 vaccines

Topics
Hosted by
Mentioned
#136 - AMA #17: Body composition methods tour de force, insulin resistance, and Topo Chico #138 - Lauren Miller Rogen and Richard Isaacson, M.D.: Alzheimer's disease prevention—patient and doctor perspectives

Episode Stats


Length

1 hour and 36 minutes

Words per minute

199.68

Word count

19,187

Sentence count

1,275

Harmful content

Misogyny

2

sentences flagged

Toxicity

7

sentences flagged

Hate speech

8

sentences flagged


Summary

Summaries generated with gmurro/bart-large-finetuned-filtered-spotify-podcast-summ .

Dr. Paul Offit is a pediatrician specializing in infectious diseases, and he's an expert on vaccines, immunology, and virology. He's the Director of the Vaccine Education Center and a Professor of Pediatric Pediatrics in the Division of Infectious Diseases at CHOP, the Children's Hospital of Philadelphia, and the Perlman School of Medicine at the University of Pennsylvania. And he's on the FDA Committee for Biologics Evaluation and Research, Vaccines and Related Biological Products Advisory Committee, which is overseeing the unprecedented scale with which vaccines are being put into a pipeline to be evaluated for COVID. And as if all of the above were not enough, he's also the co-inventor of the rotavirus vaccine.

Transcript

Transcript generated with Whisper (turbo).
Misogyny classifications generated with MilaNLProc/bert-base-uncased-ear-misogyny .
Toxicity classifications generated with s-nlp/roberta_toxicity_classifier .
Hate speech classifications generated with facebook/roberta-hate-speech-dynabench-r4-target .
Topics generated with Qwen2.5-3B-Instruct.
Hosts, guests, and mentioned names generated with spaCy (en_core_web_sm), reconciled against Wikidata.
00:00:00 Hey, everyone. Welcome to the drive podcast. I'm your host, Peter Atiyah. This podcast,
00:00:15 my website, and my weekly newsletter all focus on the goal of translating the science of longevity
00:00:19 into something accessible for everyone. Our goal is to provide the best content in health
00:00:24 and wellness, full stop. And we've assembled a great team of analysts to make this happen.
00:00:28 If you enjoy this podcast, we've created a membership program that brings you far more
00:00:33 in-depth content. If you want to take your knowledge of this space to the next level,
00:00:36 at the end of this episode, I'll explain what those benefits are. Or if you want to learn more
00:00:41 now, head over to peteratiyahmd.com forward slash subscribe. Now, without further delay,
00:00:47 here's today's episode. I guess this week is Dr. Paul Offit. Paul's a pediatrician specializing
00:00:55 in infectious diseases, and he's an expert on vaccines, immunology, and virology. He's the
00:01:00 director of the Vaccine Education Center and a professor of pediatrics in the Division of
00:01:05 Infectious Diseases at CHOP, the Children's Hospital of Philadelphia. He's also a professor
00:01:09 of vaccinology at the Perlman School of Medicine at the University of Pennsylvania. And he's on the
00:01:15 FDA Committee for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory
00:01:21 Committee. In other words, he's on the FDA Committee that is overseeing the basically unprecedented scale
00:01:28 with which vaccines are being put into a pipeline to be evaluated for COVID. He's also the co-inventor
00:01:35 of the rotavirus vaccine, as if all of the above were not enough. I've wanted to talk with Paul for a
00:01:41 couple of months, but I wanted to wait until the time was right. And I kind of define that as a moment
00:01:46 when we had enough certainty in terms of what was going on with COVID vaccines that we could speak
00:01:53 about it in less abstractions and more straightforward terms with respect to likely releases and approvals
00:02:01 of various vaccines. And so I'm really glad that actually we waited until this time, because I do
00:02:05 think we're at that point where we have a pretty clear line of sight into the pipeline of a number of
00:02:13 companies and also a number of strategies that are being employed. And that's basically what we go
00:02:18 into. I mean, we certainly talk about Paul's background, which is fascinating and why he's
00:02:23 sort of the perfect guy to have this discussion. But the meat of this discussion really focuses on
00:02:28 delineating the four strategies with which one can pursue a vaccination against the virus that causes
00:02:34 COVID. And then we talk about basically who the major companies are in each of those categories,
00:02:41 where they are in their life cycle, what that actually means and what it implies as far as
00:02:47 vaccination approval. We talk a lot about what the potential risks are in each of the categories and
00:02:52 more broadly. And ultimately, we talk about what 2021 could look like and what the unknowns are.
00:02:58 So I learned a lot in this episode, actually, more than I expected. I was just completely riveted
00:03:04 by Paul's insights. And I think we all have a little bit of COVID fatigue at this point. That's
00:03:09 understandable. But I think anybody who's got questions about, will a vaccine change my life?
00:03:15 What should I expect next year? I think, and I hope at least most of your questions are going to be
00:03:20 answered here. And I don't suspect this is the last time that Paul and I will speak.
00:03:24 So without further delay, please enjoy my conversation with Paul Offit.
00:03:28 Paul, thank you so much for making time to sit down with me today. I know that you are someone
00:03:39 who a lot of people want to talk with, especially now that people are really starting to come to
00:03:44 grips with the fact that a vaccine for the coronavirus is going to be a very important
00:03:49 part of the story. I guess before we get that, though, I think it's important for people to
00:03:53 understand why your thoughts on the subject are important. In other words, you're not just someone
00:03:58 like me who's been thinking about the coronavirus for less than a year. You're someone who has spent
00:04:03 essentially a lifetime thinking about this type of a problem. There's a story about how you were
00:04:08 a very young boy, you were hospitalized, and that experience at such a young age kind of shaped the
00:04:15 way you thought about going into medicine and ultimately even being a pediatrician. Can you share a bit
00:04:20 of that? Sure. So I was born with clubbed feet, which means that my feet turned sort of inward and
00:04:26 down. Typically, that's treated with casting. So I was casted when the first few hours of life,
00:04:31 really. And then so for months, I was casted, but it seemed to work. I mean, my feet seemed to
00:04:36 straighten out. But at the age of five, my father decided that he didn't like the way that my heel
00:04:40 didn't, or my right foot didn't hit the ground as well as he would have liked. So he was able to find
00:04:46 a surgeon to do a surgery, frankly, that was perfected about 40 years later. We should have
00:04:51 never done that surgery. There was no clubfoot surgery. He was able to find a guy who was a son
00:04:56 of a friend of his who had just finished his residency in orthopedics and thought, great,
00:05:00 I get to do this surgery, which went badly. My father was a shirt manufacturer. Medicine wasn't
00:05:06 really his strength, but he didn't like the way that heel hit. Interesting as a side part of the story
00:05:11 is that my great uncle, my grandfather's brother was a bookie. He was really Baltimore's bookie.
00:05:16 He didn't print books. He made book. My mother initially had trouble getting me into the club
00:05:21 foot clinic at Johns Hopkins Hospital. But she just called my great uncle who called the guy who was
00:05:26 head of the foot clinic, who was a gambler, apparently. So we got in within a week. And when
00:05:30 the guy, this physician saw me, he said, if you do nothing, don't operate on this foot. Nonetheless,
00:05:36 my father insisted the foot be straighter. And so I had an operation that was a complete failure.
00:05:40 And as a consequence, I ended up in a chronic care facility called Kernan's Children's Hospital.
00:05:46 Although I think then it may have been called Kernan's Hospital for Crippled Children,
00:05:49 when you could use words like crippled and feeble-minded. I was there for about six weeks.
00:05:54 And this was the 1950s. The polio was king. And I remember just a lot of children in that ward
00:05:59 with polio. It was probably about 20 kids in the ward, some in our lungs, some in traction.
00:06:05 And there was one visiting hour week. That was it. Sundays from two to three,
00:06:08 my mother had a complication with pregnancy with my brother. So she never came. My father had tried
00:06:13 to sneak in once to see me. Thus was prohibited from seeing me again. So he traveled a lot. So
00:06:18 he couldn't do the hours that they had wanted him to do. So I just remember sort of seeing those
00:06:24 children as vulnerable and helpless. And in fact, seeing myself the same way. And I remember
00:06:28 looking, there was up, my bed was next to a window. This was when you had one visiting hour a week,
00:06:33 polio day. So people were scared to death of having anybody else come into that hospital.
00:06:36 Sundays from two to three. It wasn't like they had like therapy dogs or, you know, iPads or
00:06:42 televisions or anything. You just pretty much laid there. And in my case, looked out the window that
00:06:47 was right next to my bed, which looked out into the front door. And I kept waiting for my parents
00:06:51 to come rescue me to walk through that front door of the hospital. Never happened. When I was a medical
00:06:57 student at the University of Maryland, we rotated through Kernan's Children's Hospital. And that room
00:07:01 was still there. It wasn't a polio ward anymore. It was a group of secretaries, but that window was still
00:07:06 there. That festivity is still there, isn't it? Yeah. Kernan's Children's Hospital is still there.
00:07:10 I did my residency at Johns Hopkins. And I remember we would sometimes get transfers. I was in surgery.
00:07:16 So kids that would get infections that would need to be transferred to Hopkins for surgical care.
00:07:22 That's funny. I didn't think I'd hear that name again.
00:07:24 So I remember as a student then, I was at Merrill Medical School, but I remember walking up to
00:07:28 that window and looking out of it and seeing that front door. And, you know, I cried. So I think that's
00:07:33 it. I mean, I think that we are motivated by the scars of our youth. For me, a choice to go into
00:07:38 pediatrics, a choice to go into pediatric infectious diseases, a choice to write a book about
00:07:42 polio, specifically about a sort of a tragic event associated with the making of the polio
00:07:46 vaccine, a choice to make vaccines, I think, enter the world of science and stuff. Probably all is
00:07:50 motivated by the scars. Pretty much every book I've written, at its heart, child advocacy,
00:07:55 at its heart, sort of standing up for children who are vulnerable, who can't stand up for themselves.
00:07:58 We're going to talk about vaccines today. And I don't think a discussion of vaccines would be
00:08:03 complete without saying something about just the unbelievable disservice that has been done to so
00:08:11 many people, so many vulnerable people, specifically parents who are looking for answers when maybe there
00:08:18 are no answers by sort of the fraud that was catapulted upon them in the late nineties in the form of
00:08:25 that Lancet article that has been so thoroughly debunked as not just incorrect, but outright
00:08:32 fraud. Of course, I'm referring to that Wakefield paper of 12 completely fabricated case studies
00:08:38 that really on some level is kind of a big part of the anti-vaccine rhetoric and the vaccines cause
00:08:49 gastrointestinal disease, which causes autism story that started at that time. And frankly,
00:08:55 on some levels, there's a solid number of people who continue to believe this, despite the efforts
00:09:00 of people like Brian Deer, yourself, Peter Hotez, people who have so thoroughly debunked that type
00:09:07 of nonsense. How do you process that? Do you process it? There are some people who are very angry
00:09:14 about the anti-vaccine movement. There are others who I think speak to it more from a place of empathy.
00:09:20 How do you manage your own emotions around that, especially when you see the children themselves
00:09:25 are often the victims of parents who are themselves the victims, et cetera?
00:09:31 Yeah, I guess I come out on the angry side. I think Andrew Wake was a fraud. I think at some level,
00:09:36 he was a knowing fraud. I mean, he misrepresented clinical data. He misrepresented biological data.
00:09:42 That paper should have never been published. It was basically a story of 12 children,
00:09:45 eight of whom had autism, presumably within a month of receiving MMR vaccine, when in fact,
00:09:50 at least a couple of the children had developed signs and symptoms of autism before ever having
00:09:54 received that vaccine, which he knew. He also, he had biopsies on all those children and presumably
00:09:59 measles vaccine virus was supposed to be destroying intestinal epithelial cells. He had biopsies on those
00:10:04 children. He never did studies looking at, or at least never reported studies, looking at whether
00:10:08 there was measles virus genome or measles virus vaccine proteins in those cells, which is to say
00:10:13 he probably did do those studies and they didn't come out the way that he wanted them to.
00:10:17 Actually, we'll go one step further. I think Brian Deer has actually done a very good job uncovering
00:10:21 those biopsies were done and processed. And the amount of virus that was found in them was identical
00:10:31 to that, which was found in basically the formal in itself, demonstrating that it was a pure
00:10:38 contaminant. So actually there was no measles virus whatsoever in any of the colons of, or distal
00:10:46 ileums of any of those children. And I talked to a person who did some of the serology with
00:10:50 Andrew Wakefield for a meeting I had in England, and he refused to be on the paper because he felt that
00:10:55 Andrew Wakefield had basically misrepresented sort of IgM, IgG response, immunoglobulin responses to
00:11:00 measles. That was Andrew Wakefield. Brian Deer just wrote a book called The Doctor Who Fooled the World,
00:11:05 which goes through all this. I'll be interviewing Brian because I think it's such an important
00:11:10 discussion. Clearly there's no shortage of anger towards Wakefield because I agree with you.
00:11:16 And by the way, fraud and knowingly is a bit of a tautology. By definition, if it's fraud,
00:11:21 in my opinion, he was knowingly acting in bad behavior. And where are we today? Maybe just
00:11:27 talk about it through the geography that you understand best, which I assume is the United
00:11:31 States. Where are we at MMR vaccination levels? Are we above 95%? We were. I mean, I think what
00:11:38 happened with the COVID-19 pandemic is that we had a dramatic drop in the instance of vaccines in
00:11:42 general, including MMR vaccine. But I would say this, I think that this is going to probably surprise
00:11:46 you. I think in some way, Andrew Wakefield was good for science. Here's why. When he put that
00:11:53 out there, he became a darling of the anti-vaccine movement. He was attractive. He was well-spoken.
00:11:59 He had a British accent, which we all love. I think we're ready to give ourselves back to the
00:12:02 queen at this point. And he made the rounds in the United States. He was on everything,
00:12:06 morning, evening shows. He was on 60 Minutes with Ed Bradley. He was a darling of the anti-vaccine.
00:12:12 He was a physician, a scientist who now said all the right things. And I think the anti-vaccine
00:12:17 folks attached themselves to his star. When it was found out that he was not only wrong,
00:12:22 but fraudulent and wrong, that he not only had misrepresented clinical and biological data,
00:12:26 but in fact had basically laundered money, laundered legal claims through a medical journal,
00:12:32 his star fell. And I think the mainstream media rejected him. His last, I think,
00:12:37 appearance on mainstream media was on Anderson Cooper.
00:12:39 Where Cooper just destroyed him. Yeah.
00:12:42 Yeah. It was great. So at some level, he helped us marginalize to some extent the voices that were
00:12:49 the anti-vaccine voices, Barbara Lowe Fisher, Jeff Schwartz, J.B. Hanley, et cetera, had a much bigger
00:12:54 voice, I think, 20 years ago, 15 years ago than they do now, because I think mainstream media anyway
00:12:59 has chosen to set them aside. And obviously their platform is social media, but so I think Wakefield in
00:13:04 some ways helped us. I mean, we did the studies to answer the question, whether you were more likely
00:13:09 to develop autism, if you've got the MMR vaccine or not, that's been done 18 times in seven different
00:13:13 countries on three different continents. The question has been asked and answered. I do think,
00:13:18 according to a study done by the Autism Science Foundation, about 85% of parents who have children
00:13:22 with autism no longer believe that vaccines were the cause. So I do think that that good science did
00:13:27 win out to some extent. And I think Andrew Wakefield has lost that. He's now, you know,
00:13:30 he goes on Alex Jones' show, where all good conspiracy theorists go.
00:13:34 Paul? Yeah, it's interesting. There aren't many things in medicine we can say with a higher degree
00:13:39 of certainty, actually, than the MMR vaccine does not cause autism. If you really stop to think about
00:13:45 it, Paul, do statins cause Alzheimer's disease? I think the data is overwhelmingly convincing that
00:13:50 it does not. But I think the data are more convincing than MMR does not cause autism based on the extent to
00:13:57 which it's been studied. And maybe to some extent, the negative attention that Wakefield has brought
00:14:04 to this has actually forced so much scrutiny of those data, not just the 18 studies you refer to,
00:14:13 but also going back and really exposing the biological plausibility of the argument itself.
00:14:21 And frankly, exposing another issue that I think is very easy to understand. So I say this with a lot
00:14:30 of empathy, but is nevertheless an issue, which is any of us are capable of misremembering facts.
00:14:37 And so much of what I think gave Wakefield and his associate Barr, the lawyer with whom you referred
00:14:46 to earlier, that he was basically in cahoots, siphoning funds through his research organization,
00:14:52 the ability to carry on for so long, was effectively parents misremembering things.
00:14:58 I actually believe most of those parents were not nefarious. I think there are some that who clearly
00:15:03 were. I think there were some who consciously chose to sort of pursue legal action to get money,
00:15:11 knowing that what they were saying was false. But I don't think that that's the majority of them.
00:15:15 Because remember, all of those parents in that case said, little Susie got the vaccine on Tuesday,
00:15:21 had a nosebleed on Wednesday, had a fever on Thursday, and started banging their head against
00:15:26 the wall. And the rest is history. I actually think they believed that. Although the medical
00:15:31 records showed, no, actually, little Susie stopped talking six months before they ever got the vaccine.
00:15:38 And here are the medical records to demonstrate it. I mean, it was unambiguous what had happened.
00:15:42 But I just think that people, ourselves included, sometimes struggle when we go back to remember
00:15:48 things, especially things that are painful. I think we look for reasons for why things happen.
00:15:54 That gives us some level of control, even though the reason may not be the correct one. At least now we
00:15:59 feel like we have some handle on it. What Andrew Wakefield offered at some level is hope. If you don't
00:16:04 want your next child to get autism, separate the MMR into its three component vaccines. If you want to
00:16:08 treat this child, here's a variety of intestinal treatments that will work, that will be magical.
00:16:14 I mean, he was a charlatan of the first order because he took advantage of parents' desperate
00:16:20 desire to do something for their children. And not to get too far into Wakefield's psyche,
00:16:24 but I actually believe there was probably a day when he was honest. I believe there was a day when
00:16:30 he, like any scientist, had a hypothesis, set out to test it. The difference is he crossed a line.
00:16:37 The difference between a good scientist and a bad scientist and a charlatan
00:16:40 is that a good scientist can look at the data when they disagree with hypothesis and modify
00:16:46 hypothesis. He had done some early work on sort of vasculitis associated with
00:16:51 inflammatory bowel diseases. Yeah. He tried to really make the case that measles-containing
00:16:55 vaccine also was a cause of inflammatory bowel disease. He was wrong, and he admitted he was wrong.
00:16:59 And then he went on to the next thing where he was wrong, but didn't admit he was wrong.
00:17:03 Yeah. And doubled down. And that's where really the fraud got out of control.
00:17:06 So let's take a step back to give people a bit of a sense of your work. What were you doing? What
00:17:13 was a day in the life of Paul Offit a year ago, basically before SARS-CoV-2 was a known entity?
00:17:21 What were you working on? I spent 26 years of my life working on creating the strains of virus that
00:17:26 became the bovine human reassorting vaccine rototech. That was my 26-year effort. Before that was done,
00:17:31 about 2000, we created the Vaccine Education Center at Children's Hospital of Philadelphia,
00:17:35 which sort of creates and distributes educational materials to educate the press, educate the public,
00:17:40 educate doctors about vaccines so we can sort of meet this anti-vaccine movement, or at least the
00:17:46 anti-vaccine sentiment that people have so that we can answer their questions. What we're trying to
00:17:51 avoid is, are those children who suffer needlessly by not getting vaccines that would protect them?
00:17:56 So that's been the passion. I mean, I think the passion for me came because I think I saw how hard
00:18:01 it was to make a vaccine, how hard it was to prove that a vaccine was safe and effective, and how easy 0.98
00:18:05 it was to damn them. That paper was awful. It should have never been published. And yet it created a 0.99
00:18:10 movement, or at least supported a movement. So I think that was it. Seeing how hard vaccines were to
00:18:15 make, how easy it was to damn them got me interested in trying to fight with facts. 0.80
00:18:21 Let's talk a little bit about rotavirus. Can you tell folks a little bit about what that is and 0.84
00:18:24 how often it afflicts children?
00:18:27 Rotavirus is a virus that affects the small intestine. It causes fever, vomiting, and diarrhea,
00:18:31 primarily in children between six and 24 months of age. In the United States, before there was a
00:18:36 vaccine, everybody would be infected by age five. All children would be infected by age five.
00:18:40 And it would cause about 75,000 children to be hospitalized in this country every year with
00:18:45 severe dehydration or water loss. It would also cause about 60 children to die every year.
00:18:50 In the developing world, or in the rest of the world, it was a killer. I mean, it was really the 1.00
00:18:54 biggest killer of infants and young children, killing about 500,000 babies a year, typically
00:18:59 children less than two years of age, about as many as 2,000 a day. So there was always a lot of
00:19:05 interest in trying to make a vaccine to prevent it. That's where I came in.
00:19:08 And obviously, the difference between why so few kids would die in the United States
00:19:14 versus the rest of the world presumably had to do with supportive care. And these children in
00:19:19 the developing world were going to die of dehydration and or electrolyte imbalance. Whereas
00:19:23 in the United States, despite how many were hospitalized, at least they could receive
00:19:27 intravenous fluids in some form and perhaps even parenteral nutrition if necessary. Is that the
00:19:32 fundamental distinction?
00:19:33 The story that I tell is that there was a friend of mine who was a PhD in chemistry. She actually worked
00:19:37 for a pharmaceutical company. Her baby got rotavirus infections. So she took the baby to
00:19:42 the doctor and the child was severely dehydrated. The doctor said, let me call an ambulance and take
00:19:47 this child to a local hospital. The mother said, no, I can take her. I'll put her in the car and take 0.93
00:19:51 her. So she gets her in the car and then she's in a major traffic jam, which is why you get an
00:19:56 ambulance. And so she was stuck and she was much longer to get to the hospital than she would have
00:20:01 others. By the time she got to the hospital, the child was out of it. So they whisked the child back
00:20:05 into the treatment room. They were able to do a cut down essentially in the child's neck to thread
00:20:09 a catheter down because that was the only vein they could find. That child dies in the developing
00:20:13 world because you don't have the kind of equipment to do that cut down because you're walking 20 miles
00:20:18 to get to a clinic or hospital. So the difference between this country and other countries where
00:20:23 children die is not severity of disease. It's as severe here. It's just that we have the resources
00:20:28 here to keep children from dying.
00:20:30 So what type of a virus is a rotavirus? Is it an RNA or a DNA virus?
00:20:33 It's a double-stranded segmented RNA virus.
00:20:37 Does that pose any challenges for creating a vaccine against it?
00:20:41 The good news is when you're trying to make a vaccine, you want to see clear evidence that
00:20:45 natural infection can induce protection against at least moderate to severe disease.
00:20:49 Then you know that you should be able to mimic that part of the immune response that's associated
00:20:53 with that protection. Those studies were done in the 70s, actually. Ruth Bishop published a paper
00:20:58 showing that if you got a rotavirus infection in your first year of life, when you were then
00:21:01 subsequently challenged with the virus, again, just naturally, you could get mild infection
00:21:06 or you could get asymptomatic infection, but you wouldn't get moderate to severe infection.
00:21:09 The minute that paper was published, we thought, okay, we can make a vaccine. We just have to mimic
00:21:12 that part of the immune response that's associated with protection.
00:21:15 And was that protection lifelong, Paul?
00:21:17 No. No. Like many mucosal viruses, rotavirus, influenza virus, paraflu, respiratory syncytial
00:21:24 virus, those viruses, which have generally short incubation periods, meaning time from when you're
00:21:29 first infected to when you get sick, which generally don't have viremia as part of pathogenesis,
00:21:33 their natural infection and immunization induces protection that is short-lived and incomplete,
00:21:38 meaning decades and meaning protection against moderate to severe disease, but not mild disease.
00:21:44 These are the mucosal viruses, which I think brings us to SARS-CoV-2.
00:21:46 So I think that's going to be the same story here.
00:21:49 Did that paper in the 1970s offer an insight into whether the immunity was provided more by the
00:21:55 B cells or the T cells?
00:21:57 The thinking was that it was going to be an antibody response at the intestinal mucosal surface. We had
00:22:01 to induce an antibody response that was active at the intestinal mucosal surface, which made us think
00:22:06 it was going to have to be an oral vaccine, which stimulated then immunity at the intestinal
00:22:10 mucosal surface and not a parenteral vaccine, which would stimulate systemic immunity.
00:22:14 So what was the approach you took then to do that? In the spirit of that, at the time,
00:22:19 what were the options available? I mean, beginning with, say, a live attenuated virus,
00:22:23 is that generally the first thought an individual has when pursuing a vaccine? Or how did you guys
00:22:29 problem solve around the different ways in which you could induce immunity?
00:22:31 The way we saw it was that rotoviruses are ubiquitous. Every mammal that walks the face of this earth
00:22:39 has its own unique strain of the rotavirus. And species barriers are pretty high, meaning that a
00:22:44 cow rotavirus or calf rotavirus would cause disease in calves, but not people, and vice versa. Human
00:22:49 rotoviruses would cause disease in babies, but not calves. So we basically took advantage of that. It was
00:22:55 a generic approach, if you will, an Edward Jenner-like approach. I mean, Edward Jenner basically
00:22:59 used a cow virus to protect against human smallpox virus. So cow smallpox, essentially cowpox would 0.57
00:23:06 protect against human smallpox because they were antigenically related enough that immunization
00:23:10 with one could protect you from a disease caused by another. That was our approach. So that was our
00:23:14 initial approach, was just to take a cow virus, a calf virus that had caused diarrhea, adapted to growth
00:23:19 in cell culture, and then use that as our vaccine. And it did work, but it was inconsistent. So then we had
00:23:25 to modify that calf virus so that it included the genes that coded for the proteins that evoked what
00:23:32 we found were neutralizing antibodies. There were two surface proteins of the virus, and we thought
00:23:36 both independently evoked neutralizing antibodies. That's what we proved. So then it was a matter of
00:23:41 just constructing these combination virus, so-called reassortant viruses, between calf and animal strains
00:23:46 that became the vaccine, thus summarizing 10 years' worth of work in about 35 seconds. It's a little
00:23:53 depressing that you can do that, but that's what we did. What were the risks associated with the
00:23:58 vaccine? You don't know. Whenever you're dealing with something that's unknown, it's through calf
00:24:02 viruses. Will they behave differently in people? Will they cause something that's untoward that you
00:24:06 hadn't thought about? What we learned from other researchers was that surprisingly, actually, there was
00:24:12 a vaccine that was introduced in the late 1990s. It was made by National Institutes of Health in
00:24:16 collaboration with Wyeth called Rotashield, which was a simian rotavirus that was also a recombinant virus.
00:24:23 Simian human reassortant rotavirus that was found to be a rare cause of intussusception, which is
00:24:28 intestinal blockage. It occurred in, depending on who you read, between 1 in 10,000 and 1 in 30,000
00:24:33 recipients. It wasn't picked up pre-licensure because the studies wouldn't have been big enough
00:24:36 to pick it up pre-licensure. It was only picked up months after licensure, and then it was off the
00:24:40 market within 10 months. So that was a sobering experience. Just to relate it to today, if you don't mind,
00:24:46 that virus, rotavirus, had been studied for 50 years by that time. I mean, it was known to be an animal
00:24:52 pathogen in the 40s. Veterinarians studied it. We knew it was a human pathogen by the 70s. When
00:24:57 that vaccine came out in the late 1990s, we had 50 years worth of study. Nonetheless, it caused a
00:25:02 side effect, intussusception, that would have never been predicted by all those studies.
00:25:06 Yeah. Let me tell people what that is. So an intussusception is when usually a lymph node in the
00:25:11 small intestine acts as a foci and allows the small bowel to telescope on itself. So it gets tugged
00:25:19 probably through some sort of peristalsis action, and that can cause an obstruction. So if the piece
00:25:26 of the bowel telescopes into another and comes back out, easy peasy. But if it telescopes and gets
00:25:31 stuck, you now have a bowel obstruction. And I took care of many kids, as I'm sure you have,
00:25:36 who had intussusception from lymphoid hyperplasia or various other things. But obviously in this case,
00:25:41 it was a side effect of a vaccine and an understandable side effect, meaning there's a
00:25:44 biological plausibility of why giving a vaccine that has a GI mucosal effect could lead to lymphoid
00:25:52 hyperplasia that could act as the tugging point. But you're right. You would never in a million years
00:25:57 say, I think intussusception could be a side effect here. And if it only occurs one in 10,000 cases,
00:26:04 you're going to easily miss that in phase one, two, and phase three. Again, it speaks to
00:26:09 aftermarket surveillance and the absolute imperative of it. And it also speaks to the fact
00:26:14 that as we start to talk about coronavirus, which we're going to get to very shortly,
00:26:18 one has to be thoughtful about risk versus reward trade-off with small n, right?
00:26:23 Yeah, I think that the surprise was that vaccine, which was sort of a simian rotavirus-based vaccine,
00:26:29 that virus reproduced itself far less efficiently at the intestinal mucosal surface than did
00:26:33 wild-type virus, natural virus. There was no evidence that natural rotavirus caused
00:26:37 interception. So why would this be true? And the reason is, is that interception really
00:26:41 appeared to be a year-round phenomenon. It wasn't a winter phenomenon in the United States,
00:26:44 which was what rotavirus was. You would expect to see a bump in the winter, which you never saw.
00:26:48 So why would a vaccine do something that natural infection didn't do? I think what we know now is
00:26:52 that natural infection probably was a very rare cause of interception, as was this vaccine. And
00:26:57 I guess the COVID analogy is that here's a virus, COVID, for which we had at least the gene structure
00:27:02 in early January of this year, which has already had a number of sort of clinical and pathological
00:27:08 surprises, which we are now about to counter with a series of vaccine strategies with which we have
00:27:12 no commercial experience. I think it's fair to say there's going to be a learning curve here. So there
00:27:17 has to be real humility, I think, as we move forward. Let's help folks understand a little bit about
00:27:21 these different phases, because you can't turn on the news without hearing company X is in phase
00:27:27 one or two or three. And I just want people to understand what those mean specific to vaccines,
00:27:35 because they have slightly different meanings than, say, in drugs that treat blood pressure.
00:27:40 So can you explain to people what a phase one vaccine trial aims to accomplish and what a typical
00:27:47 size of that trial might look like? If you're trying to make a vaccine, you start in so-called
00:27:52 preclinical studies, meaning studies done before you get to humans. And hopefully you'll have an
00:27:57 animal model to study the disease. In the case of rotavirus, it was mice. If we inoculated baby's
00:28:01 mice with rotavirus, they got sick. Okay, great. So now we have a way to study this infection.
00:28:05 Then you have your idea for how you want to make your vaccine. You give your vaccine, you then
00:28:09 challenge the animal with the virus, and hopefully you can protect the animal from disease. And more
00:28:14 importantly, you can frankly literally dissect out that part of the immune response that's associated
00:28:18 with protection against challenge. So those preclinical studies are called proof of concept
00:28:22 studies. So now you have your way of making a vaccine. Then you go to phase one, which are usually
00:28:26 about 20 to 100 people. Now you have your idea for how you want to make it, but you don't really
00:28:31 know the dose. So you give a variety of different doses to these 20 to 100 people to see whether or
00:28:36 not you can safely induce an immune response that you think is going to be protective based on your
00:28:41 animal model work. Now you have a dose and a strategy. What's the typical length of time to go from
00:28:47 that preclinical where you've now filed an IND and you now would be applying to an institutional review
00:28:54 board to do a phase one. In the normal world, that takes how long usually?
00:28:58 I think probably it's fair to say 10 years, 15 years.
00:29:02 Okay. We'll make sure everybody keeps that in mind when we pivot to coronavirus. The other thing I want
00:29:07 to highlight that you just said there is 20 to 40 people-ish.
00:29:11 Yeah, 20 to 100.
00:29:12 We're not talking about 10,000 people.
00:29:14 No, no.
00:29:15 And these are often done with a little bit of a dose escalation built in. So maybe the first
00:29:19 10 people are going to get a really, really small dose. We make sure nothing catastrophic
00:29:24 happens. We then escalate the next 10, et cetera, right?
00:29:27 There are dose ranging trials. Exactly right. You go slow and you work your way up to see what
00:29:31 seems to consistently induce an immune response that is safe.
00:29:36 The third thing I want to highlight there is we're not actually able to assess whether or not
00:29:41 the people have legitimate immunity. We're using a proxy, presumably, which is some form of
00:29:48 serology. In other words, we're not actually testing their ability to resist an infection.
00:29:52 We're measuring an antibody. Is that correct?
00:29:55 That's right. You have a prediction based on your animal model studies that one aspect of the
00:29:59 immune response is going to be associated with protection against chance, as it was true in your
00:30:03 animal models. You won't know that until you get to phase three.
00:30:06 So now let's go to phase two. You've established a dose, potentially a frequency. What do you do in
00:30:12 phase two and roughly how many people do you do this with?
00:30:15 So phase two is typically hundreds of people. Now you've got your vaccine, you've got your dose,
00:30:19 and you just want to make sure that it's consistently induced an immune response that
00:30:22 you think is protective and that it's at least safe and that it doesn't cause a relatively common,
00:30:28 serious side effect. That's phase two.
00:30:31 And again, the two points worth making sure people understand, still a relatively small clinical trial,
00:30:38 hundreds of people, and you're still using surrogate markers. We don't actually know if this
00:30:43 vaccine is providing immunity in the real world. It's efficacy. We don't know if it's effective.
00:30:50 And we don't really have any way of knowing what very minor or I shouldn't say minor, infrequent
00:30:57 negative consequences could look like because we're still dealing with a very small sample size.
00:31:01 That's exactly right.
00:31:02 So now we go to phase three. And what does that look like?
00:31:06 This is the definitive trial. This is the trial that you're going to use to submit
00:31:10 information to the FDA, Food and Drug Administration, hopefully for licensure.
00:31:14 These are tens of thousands of people. In the case of our rotavirus vaccine, it was
00:31:19 70,000 babies. 35,000 got the vaccine. 35,000 got placebo, which is just essentially the vaccine
00:31:26 except no active ingredient, just the, frankly, sugar solution in which the vaccine virus was suspended.
00:31:32 And then you just send people out into the real world. I mean, rotavirus is a common infection.
00:31:36 It's the rare child who gets stage five without being infected. And then you just see whether or
00:31:40 not children who got the vaccine were less likely to get rotavirus, or if they got it,
00:31:44 that they were less likely to get it severely. And hopefully you'll have, we had zero on all those
00:31:49 children, meaning we looked at the antibodies on all those children. Hopefully that would provide
00:31:54 a clear immunological correlated protection, which it didn't. We knew that the vaccine worked. We knew
00:31:59 that it was safe. And so we could submit it for licensure to the FDA. But as you go along,
00:32:02 things are much more expensive. You go from sort of millions to tens of millions to hundreds and
00:32:07 hundreds of millions, and then you mass produce the vaccine after you found out that it works.
00:32:12 And as a general rule, the process we just described going from a preclinical model in animals
00:32:17 to the completion of a phase three trial with the FDA approval of an agent. Here's the rule of thumb
00:32:23 I use. Please correct me on the vaccine side. I generally say that's 20 years and $1 billion.
00:32:28 And that's usually on the drug side. Is it about the same on the vaccine side?
00:32:33 Yes. It's for 15 to 20 years with at least a billion dollars. That's right.
00:32:37 So let's now talk about coronavirus and just understand that in January of 2020, when the
00:32:47 sequence of the RNA identifying this as a novel pathogen, a coronavirus named now SARS-CoV-2 shows up.
00:32:55 And by March, I guess it becomes pretty clear, this is not going to be contained,
00:33:01 which means any strategy towards containment is going to fail. It became readily apparent that a
00:33:07 vaccine was going to be a very important piece of the strategy. Basically at that point, it was going
00:33:12 to be herd immunity without vaccine or herd immunity aided by vaccine. If you're staring down the barrel
00:33:18 of it's going to take 20 years and a billion dollars, that's not a very appealing strategy because
00:33:22 it basically says it has to be herd immunity without a vaccine, meaning this virus has to sort
00:33:27 of rip through a population without it. If I could ask you to put yourself back in your mindset in
00:33:33 February or March of last year, what would you have said if I asked you at the time, Paul,
00:33:39 how likely is it that a vaccine will be developed to at least thwart in some way this virus? And two,
00:33:45 how long will it take? What would you have said then?
00:33:48 I would have said it would take years. You do have to give credit to the administration for one
00:33:52 thing. Operation Warp Speed, what they did was they basically took the risk out of it for
00:33:58 pharmaceutical companies. What the government said is both BARDA, which is part of Health and Human
00:34:03 Services, the Wealth Health Organization, the Gates Foundation and others, but in this country,
00:34:06 the government said, here's what we'll do. We'll pay for phase three trials. We'll pay for mass
00:34:11 production at risk, meaning we'll mass produce this vaccine. We'll make millions of doses of vaccine
00:34:16 without knowing whether the vaccine works, without knowing whether it's safe, and showing a
00:34:20 willingness to, if it neither works or isn't safe, we'll throw out those tens of millions of doses.
00:34:24 No pharmaceutical company would ever do that. So now you basically had phase one trials. You
00:34:29 pretty much went right to phase three trials, which a company would never do. Went right to mass
00:34:33 producing, which a company would never do. And that's what meant having a vaccine in hand in
00:34:38 January. It is in all likelihood that we will have a vaccine that is rolling off the assembly line
00:34:43 into the arms of Americans by early next year. I mean, so a year and a quarter to make a vaccine
00:34:49 with only having the virus in hand in January. That's remarkably fast. It's unimaginably fast,
00:34:57 but it's the government that did that. So give credit to them. Let's talk a little bit about some
00:35:01 of the different ways in which vaccines are made. Again, there's so many different ways to skin this,
00:35:06 but one way is you actually deliver the RNA of the coronavirus in a vehicle that then gets taken up
00:35:15 by our DNA, and it creates enough of an immune response that we create an immune response to it.
00:35:21 How do you think of that overall strategy?
00:35:24 So if there's any good news about this virus, it's that we know the part of the virus, the protein in
00:35:30 the virus that attaches the virus to cells. If you can prevent the virus from attaching to cells,
00:35:35 in theory, you should be able to prevent the virus from infecting cells or, said another way,
00:35:39 infecting you. That protein is the spike protein. It's the protein that emanates from the surface of
00:35:43 the virus. It gives it its crown-like appearance, hence coronavirus. You also know the gene that codes
00:35:49 for that protein. It's an mRNA virus, meaning messenger RNA virus, single-stranded messenger RNA virus
00:35:56 like rubella or germane measles. So the initial strategies to make this vaccine are all based on that
00:36:02 knowledge. We know the gene that codes for that protein. Take the mRNA strategy, which is the most
00:36:08 naked and obvious, which is that you basically take the messenger RNA, which codes for that protein,
00:36:14 you inject it into people, it's taken up by the cell in the cell cytoplasm outside the nucleus,
00:36:20 it enters the so-called ribosomal system, and it's translated to a protein, which is excreted.
00:36:24 So that's your body makes the coronavirus spike protein, then your body makes antibodies to the
00:36:30 spike protein. This very similar strategy is the so-called DNA vaccines, and then these so-called
00:36:35 replication defective, simian or human adenovirus vaccines, or replication competent vector vaccines,
00:36:42 all have the same strategy in mind, which is introduce the gene that codes for the coronavirus
00:36:47 spike protein, induce your body to make that spike protein, and then your body will make antibodies.
00:36:52 These are so-called genetic plug and play vaccines. The reason that they're the first ones to come out
00:36:58 is because they're the easiest to construct and the easiest to mass produce. It doesn't mean they're
00:37:03 going to be the last best vaccines, but that's why they're going to be the first vaccines.
00:37:08 One question I have for you on that, Paul, is given the instability of RNA, I've always been kind of
00:37:12 surprised that they work. I can understand why DNA could work, but given how unstable RNA could be,
00:37:20 when you take a single strand of messenger RNA and deliver it, what allows it, I mean, this might
00:37:26 sound like a silly sort of technical question, what allows it to make its way into our cells,
00:37:33 into the cytoplasm, head over to the ribosome, and then get translated ultimately into protein?
00:37:40 So anybody who works with messenger RNA in a laboratory stores messenger RNA at minus 70 degrees
00:37:46 centigrade or in liquid nitrogen, because as you say, it's an incredibly labile molecule. It breaks
00:37:51 down within moments, frankly. I've burned myself on said vats of liquid nitrogen many a time in the lab.
00:38:00 Yeah. So to get around that problem, these vaccines, the messenger RNA vaccines have to be
00:38:06 encapsulated in a complex lipid delivering system, which stabilizes them to some extent.
00:38:11 And the Moderna has been able to figure out a way to both store and ship and store at minus 20
00:38:18 degrees, which is just freezer temperature. But Pfizer, no, they're going to ship and store at
00:38:22 minus 70, minus 80, this sort of ultra cold chain, which we've never done in this country, which I
00:38:26 think will be a challenge. So you have to constantly maintain that product on dry ice. Once you thaw it
00:38:31 out and put it in the refrigerator, it can't be there for more than a day before you give it.
00:38:35 You're right. I think the lability of messenger RNA will be a challenge here. And just one sort of
00:38:39 nerdy virologist thing that I'd like to say as a nerdy virologist is that when you're infected
00:38:45 with this virus, you'll shed infectious virus for a week, roughly. You'll shed infectious virus for
00:38:50 a week. You'll be PCR positive, polymerase chain react positive. You can be PCR positive for three
00:38:56 months. What you're detecting in the back of the throat is not infectious virus. It's messenger RNA.
00:39:01 That's what you're detecting, which means because it's so quickly degraded, why would it be around so
00:39:06 much longer? And the answer is the virus is continuing to make messenger RNA, but not making
00:39:11 whole virus particles. Why would it do that? I mean, this virus continues to surprise, I think.
00:39:17 Let me make sure I understand what you just said, because I never actually thought about it that way.
00:39:23 You're saying that, let's say I take the Moderna vaccine. I'm getting a bolus of mRNA. My body is going
00:39:30 to just take that and incorporate it and start kicking off protein, but it does two things. It
00:39:36 doesn't just take it like one single transcribed piece of mRNA and translate it into protein and be
00:39:42 done with it. It actually incorporates it back into the DNA and that cell of mine continues to
00:39:50 transcribe and translate it. Is that what you're saying for months? The mRNA will amplify itself in
00:39:55 the cell. True. Which cell? Epithelial cells? Like which of my cells? Muscle cells. You'll be
00:40:01 inoculated in your arm. It'll be the muscle cells. And then to some extent, also antigen presenting
00:40:05 cells like macrophages, dendritic cells. Okay. That's kind of interesting to think about because
00:40:11 why would it show up in a throat swap? How is it making it all the way to the epithelial cells in my
00:40:17 throat or in my nose or wherever? I guess I'm saying two different things. When you're naturally
00:40:21 infected with SARS-CoV-2, that virus then reproduces itself over and over again, part in the back of
00:40:27 your throat. And it makes infectious virus particles. It enters your cells. It's transcribed. It's
00:40:32 translated. And then it makes new virus particles. But what happens is it's only making new virus
00:40:37 particles for about a week. And then it stops making infectious particles anymore. But you still
00:40:42 have messenger RNA in the back of your throat. You can for months, which means the virus is still
00:40:46 there. It's still in the cell. It's still making messenger RNA, but it's not making a whole virus
00:40:50 particle anymore. That's weird. I don't know of any virus that does that. I'm not sure it says
00:40:55 anything about the messenger RNA approach. I mean, messenger RNA does amplify itself in your body,
00:41:00 but then it's quickly broken down as it's all messenger RNA in your body. It'll be curious to
00:41:05 see what happens with this. I mean, we're going to learn a lot with this strategy. We'll see whether
00:41:09 it applies to other vaccines possibilities, and we'll see whether or not we run into a problem.
00:41:14 Moderna that you mentioned is obviously one of the front runners in this. And I think that's in no 0.97
00:41:17 small part to the fact that one of their partners is NIH. That's, you know, National Institutes of
00:41:22 Health here in the United States has bankrolled to the tune of about a billion dollars, as you said.
00:41:27 Has NIH partnered with anyone else besides Moderna?
00:41:30 No, just Moderna. It's their construct that Moderna uses. The nucleoside analogs that are used in that
00:41:36 vaccine, that was all developed by a couple of researchers at the National Institutes of Health.
00:41:40 Actually, National Institutes of Health, as far as I know, holds the patent on that vaccine.
00:41:43 And they basically entered phase three this summer, correct? I mean, I think they're fully
00:41:48 enrolled, aren't they? They entered the end of July. As far as I know,
00:41:51 they're fully enrolled, but it's hard to know. I mean, it's always trying to read the tea leaves
00:41:54 on this. They're strong. Okay. Well, anyone else on the mRNA strategy that you think is,
00:42:00 I mean, Moderna is probably the leader, correct? Moderna and Pfizer, both.
00:42:05 Let's talk a little bit about the Pfizer platform. How does it differ?
00:42:08 Sure. Whereas Moderna gives 100 micrograms per dose in a two-dose series, Pfizer gives 30 micrograms.
00:42:14 So it's not the same nucleoside analogs. And I'm curious to know, I'd love to hear a scientific
00:42:19 presentation on why Pfizer needs to ship and store at minus 70, which is going to be a challenge as
00:42:24 compared to Moderna's shipping and storing at minus, just at minus 20. They are different
00:42:29 constructs. So they're given at different amounts and we'll see to what extent any of them work or
00:42:33 safe. Now, Pfizer is doing a phase two, phase three combined. Is that correct?
00:42:39 They sort of all are. I mean, you sort of went right, sort of skipped through phase two,
00:42:44 right to phase three, really. They all did that.
00:42:47 Do you think that that distinction, Paul, from a logistic standpoint is going to matter? In other
00:42:52 words, when we start to think, let's just assume for a moment that the Moderna vaccine and the Pfizer
00:42:56 vaccine have equal efficacy in the real world. So in a phase three trial, we see, call it a
00:43:03 70% reduction severity of infection in those receiving the vaccine over the placebo. Would
00:43:10 we agree that that's a win? Yes.
00:43:12 Okay. All other things being equal, is the need to transport tens of millions of doses of something
00:43:19 basically in liquid nitrogen going to pose a challenge?
00:43:23 So it won't be in liquid nitrogen, but it will be on dry ice. Is that going to pose a challenge? Yes.
00:43:28 I think what worries me in this a little bit is that when you do the studies, which Pfizer's doing
00:43:32 and Moderna's doing, you can be comfortable that the companies are very good at overseeing the
00:43:38 shipment and storage of that product. And they're making sure that the investigators, they've got the
00:43:42 special package in which this vaccine is stored. They're constantly maintaining dry ice. That
00:43:48 doesn't worry me. And when it's thawed out and put in the refrigerator, it can only be there for a
00:43:51 day. When the vaccine then gets distributed to the world under natural conditions or the United States
00:43:56 under natural conditions, how is it going to be distributed? Probably at least in part in like
00:44:01 large chain pharmacies. Are the pharmacists going to be as good at doing what was done during the
00:44:06 trial? Because certainly, as you said at the beginning, I mean, these are mRNA is labile. And
00:44:11 if it degrades and it certainly has the capacity to degrade, will we get less efficacy effect in this
00:44:17 of the vaccine in a real world situation than we did in a experimental situation?
00:44:21 Yeah. I guess TBD, your best guess of how those companies are signaling when we're going to see
00:44:30 data? I mean, it depends in large part on how active the third wave of this is, because this is one of
00:44:37 those things where the more people that get exposed, the more quickly we see the difference between the
00:44:44 placebo and the vaccine.
00:44:45 The company technically doesn't know what's going on in the trial. I mean, technically the company,
00:44:51 meaning the CEO, for example, doesn't know who's gotten vaccine, who's gotten placebo, doesn't know
00:44:56 who's gotten sick and who hasn't gotten sick, doesn't know how many cases of disease have occurred in
00:45:00 the placebo group or vaccine group, doesn't know that. The Data Safety Monitoring Board knows that,
00:45:04 which is composed of a group of academics and researchers who are not affiliated with the company
00:45:08 and not affiliated with the government.
00:45:10 These are being run through large CROs, I assume?
00:45:12 Yes. Depends on who's doing it, but yes.
00:45:16 For the listener, clinical research organizations, when large companies or even academics do
00:45:20 clinical trials, they usually contract out with companies that are exceptional at all the stuff
00:45:25 that Paul's talking about, which is the logistics of how do you actually ship this thing from A to B
00:45:30 and make sure it goes perfectly? How do you get the blood draw on this person and measure this and
00:45:34 all these things? And so that's not an expertise that a company wants to build in-house. They typically
00:45:39 outsource that. And it's those companies that are, it's a part of that is the monitoring.
00:45:43 But presumably there's a power analysis that's gone into this that said, look,
00:45:48 we're going to enroll 30,000 people. We know half of them are going to get a placebo. Half of them are
00:45:51 going to get an active agent. We've stratified on some level by age. The inclusion criteria probably
00:45:57 says we want people between ages X and Y of a certain, this many of them to be of this health,
00:46:03 this many of them to not be of that health. We think the exposure risk at this stage of the virus
00:46:09 is, meaning at this life cycle of the virus, we think there's this many more people that can be
00:46:14 exposed. The R not is something. Do you think that they can at least get back into an answer which 0.97
00:46:20 says, hey, by February, we should know this, good or bad? Or is that simply something that just can't
00:46:26 be known a priori? My hope is that these companies do what was recommended actually by the NIH active
00:46:32 group that was put together by Francis Collins, which is, it depends on whether it's a one-to-one
00:46:37 or two-to-one trial, meaning two vaccines recipients for everyone, placebo recipient or one-to-one.
00:46:43 But if that's true, you need at least around between 147 and 160 people to get sick in the trial
00:46:50 in order to be able to say you can so-called reject the null hypothesis. The null hypothesis is
00:46:55 this vaccine doesn't work. To reject the null hypothesis is to say I have statistically significant
00:47:00 robust evidence that says it does. You need 90% confidence interval to be able to say that
00:47:06 you need about 150 people. Now, their data safety monitoring board, they're looking all the time,
00:47:10 in real time. So they know when they feel you've met a safety or efficacy standard, and then they
00:47:16 call the company and they say, okay, now you can submit this vaccine. What would be for a typical
00:47:21 vaccine, which is not this vaccine, you can submit it for licensure with a biologic license application.
00:47:26 That's not these vaccines. These vaccines were all going to be permitted for use under emergency
00:47:32 use authorization. It's different. And that, I think, is what scares people at some level because
00:47:37 they saw what happened with, for example, hydroxychloroquine, which didn't work. Now it's
00:47:41 been shown clearly not to work to treat or prevent disease, yet it was approved under EUA. Or
00:47:46 convalescent plasma, which is to say antibodies taken from people who survived the infection,
00:47:50 which, again, was heartily approved by the FDA through this emergency use authorization, also
00:47:56 with no evidence that it worked. What's weird about this is that people are doing the same
00:48:00 kinds of trials they would do for any vaccine, large placebo-controlled trials, yet it's still
00:48:05 not going to go through a biological license application mechanism. It's going through EUA.
00:48:09 Just because of time?
00:48:10 I think it's because the FDA would not typically license a product that was studied for this
00:48:14 short a period of time. So yeah, because of time.
00:48:16 Can you just explain to people what the EUA is? I guess by now most people have heard the term,
00:48:20 emergency use authorization. It's been granted to not just medications, but frankly, to even
00:48:25 testing modalities. Oh, this serology test just got a EUA. This PCR test just got a EUA.
00:48:30 What does it actually mean?
00:48:31 It's a permission to use something, which is to say that even though there aren't clear data
00:48:35 showing that something is safe or effective, or that it's a diagnostic, it clearly works well.
00:48:39 We're going to allow it under this condition because we're under duress with this COVID-19 pandemic.
00:48:45 So we're going to put it out there in the hopes that it works. I actually wrote an op-ed
00:48:50 piece that I submitted to the Philadelphia Inquirer yesterday that I just heard before this show
00:48:54 that is going to be published, I think it's Sunday on the Philadelphia Inquirer. But the point I'm
00:48:59 trying to make in that piece is that how big of a risk are we taking? If we're going to be studying
00:49:02 these vaccines for four months, five months, six months, and we're going to be putting them out
00:49:07 there into millions and arguably tens of millions and hundreds of millions of people,
00:49:10 are we taking a risk? And I think in terms of effectiveness, you're only going to know
00:49:15 that a vaccine is effective for a few months. You don't know whether it's effective for nine months
00:49:19 or a year or two years. You don't know that. I don't think that's a huge risk. I think it's
00:49:22 likely that it's effective in the short term. It's probably effective in the somewhat longer
00:49:26 term. I don't think it's going to be effective for decades, but I think it's likely to be effective
00:49:30 at least for a year or two or three. I think. I mean, we'll see. And worst case scenario,
00:49:35 you could give a booster dose. That would be the worst case scenario. But then safety,
00:49:38 which is what everybody worries about. I mean, have you really studied it enough to say whether it's
00:49:42 safe? I'm on the FDA's Vaccine Advisory Committee. We had our meeting on October 22nd,
00:49:47 and that dominated the meeting. That nine-hour meeting was dominated by the FDA is basically
00:49:52 asking us, are you comfortable as a committee allowing use through EUA, knowing we're not
00:49:58 going to have a certain amount of data? What you'll have basically is you'll have two-month follow-up
00:50:02 after the last dose for safety issues. Is that enough time? Personally, I think the answer is yes,
00:50:08 I do. I mean, if you look at the serious side effects that vaccines occasionally cause, like
00:50:12 polio caused by the uropolio vaccine, which occurred in one in 2.4 million doses,
00:50:18 or narcolepsy, a disorder of wakefulness that was caused by the squalene adjuvanted flu vaccine that
00:50:23 was given in Europe, not in the United States, which occurred in roughly one in 55,000 doses.
00:50:28 Thrombocytopenia, lowering the platelet count that occurs with measles-containing vaccine,
00:50:32 which occurs in one in 25,000 doses, or something called viscerotropic disease,
00:50:36 which is basically a sort of multi-system disease caused by the yellow fever vaccine. It's basically
00:50:41 yellow fever caused by the yellow fever vaccine, which occurs in about one in a million doses,
00:50:45 or Guillain-Barre syndrome, which is this ascending paralysis, which can affect your ability to breathe,
00:50:50 that occurs in about one in a million doses of the influenza vaccine. How soon did you know that?
00:50:56 I mean, how soon did you know about those serious problems? Did you know about them within two months?
00:50:59 And the answer is yes. I was on a CDC conference call yesterday with a group of
00:51:03 folks that are associated with the Advisory Committee for Immunization Practices,
00:51:06 and we collectively could not think of a serious side effect that was not picked up after two months.
00:51:11 So I'm optimistic that that would happen here as well.
00:51:16 When you think of all of the different types of vaccines, we just talked about the mRNA vaccine.
00:51:20 We'll get to sort of the viral vectors, the inactivated or attenuated variants,
00:51:25 and then obviously just the proteins that are delivered. I want to go through these in some detail
00:51:29 and use it as an example to talk about the companies. Are there any of those classes
00:51:33 you worry about more than others from a risk standpoint? For example, some of the live
00:51:38 attenuated viruses have been the ones that go on to cause... It isn't polio is live attenuated,
00:51:43 correct? Your polio vaccine was a live attenuated viral vaccine, yes.
00:51:46 Right. And so that's presumably why you had, even though it was a minuscule risk,
00:51:50 you still had some risk of getting polio. So do you look at those four categories of vaccines
00:51:55 equally from a safety question?
00:51:57 I'm not sure we know enough about mRNA, DNA, replication defective, human or simian adenoviruses
00:52:03 to say. Here are the things that I worry about though. I worry that you've had three clinical
00:52:09 holds for these vaccines. You have one clinical hold with Johnson & Johnson's product, which was
00:52:13 a replication defective adenovirus 26. So adenovirus is a virus, human virus that causes a variety of
00:52:20 clinical diseases. Type 26 just means it's one of the many types of adenovirus, human adenoviruses
00:52:24 that cause disease. Replication defective means that the virus has been genetically engineered,
00:52:28 so it can't reproduce itself. But it has also been genetically engineered, so it contains the gene
00:52:33 that codes for the coronavirus spike protein. So that when you're inoculated with that vaccine,
00:52:38 the cell takes up that particle, which does not amplify itself. It enters the nucleus,
00:52:43 it then is transcribed, it's transcribed to messenger RNA, the messenger RNA is translated to a protein,
00:52:48 and that protein is excreted. So it's good news, bad news. The good news is it's replication defective.
00:52:53 Therefore, it can't cause disease because the virus is reproducing itself. The bad news is
00:52:57 it's replication defective, meaning you have to give a lot of virus to get enough of those virus
00:53:02 particles into the cell to make the protein you're interested in. About 10 billion virus particles per
00:53:08 dose. That's a lot of virus. That's why it is that side effect profile can be a little rough, meaning
00:53:13 fever, including high fever, and then symptoms associated with fever, chills, headache, muscle ache.
00:53:18 And that was seen fairly commonly, especially after the second dose with these vaccines.
00:53:23 Which is also part of the issue with some of the genetic engineering stuff. This is a little off
00:53:27 topic, but the use of adenoviruses for genetic engineering even 20 years ago at CHOP, right?
00:53:31 I mean, that's a big part of what kind of got into some of the trouble there, isn't it?
00:53:35 Yes. That's it. I mean, I'm at Penn. So we're all thinking the same thing, which is Jesse Gelsinger.
00:53:41 Gelsinger. Yeah. God, I still remember that story like it was yesterday. It's got to be at least 20 years.
00:53:45 He was inoculated with a replication defective adenovirus type 5 that included the gene that
00:53:51 coded for one of the liver enzymes that he was missing. He was missing a gene that allowed him to
00:53:56 take the ammonia that is a consequence of protein metabolism and excrete it from his body. So the
00:54:01 ammonia would build up in his body and then he would get very sick and go into a coma occasionally.
00:54:05 So, but he died. I mean, he died because he had a massive so-called cytokine response with
00:54:11 something called interleukin-6 at a time before we had antibodies directed against interleukin-6 that
00:54:17 would have saved his life. And we all lived through that. And it really set gene therapy back.
00:54:21 If it's any consolation, the amount of replication defective adenovirus he got was logarithmically
00:54:26 greater, exponentially greater than the amount that we're currently giving here. Even though 10
00:54:30 billion sounds like a lot, it's still about one 300th of what he got. But again, you're going into an
00:54:35 outbred population with, when you put something into millions of people, you may find something out 0.99
00:54:40 that's untoward. So yeah, that worries me. The clinical holds worried me a little bit.
00:54:45 The two clinical holds that were for replication defective simian adenovirus, which was the UK
00:54:49 AstraZeneca vaccine, were both because of neurological issues. The first was so-called
00:54:55 undiagnosed multiple sclerosis. The second was transverse myelitis, which is an inflammation of
00:55:01 a segment of the spinal cord. The mechanism by which both of those diseases happen is the same,
00:55:06 which is that you make an immune response really to the sheathing of your nerves, and particularly
00:55:11 one protein on the sheathing of your nerves, myelin basic protein. Multiple sclerosis is
00:55:15 relatively common, but transverse myelitis isn't. That occurs maybe one in 200,000 in the general
00:55:20 population. That trial was about 18,000 people big at the time, which is to say 9,000 people got
00:55:25 vaccine. And they saw that case. It was adjudicated to be likely to be coincidental and not
00:55:31 causal, but it does worry you a little bit because it certainly was a statistical bizarrety. And you'd
00:55:37 like to know what the problem was with Johnson & Johnson's vaccine, which you don't. This is the
00:55:41 problem with these things. And they're both in the same class, right?
00:55:44 They're both replication defective adenovirus. Yeah, exactly. While we're on that topic,
00:55:49 aren't these the same classes that were actually approved in Russia and China? Doesn't Russia and
00:55:55 China each have something that they've approved for limited use already in this category?
00:56:01 Yeah. So China had a replication defective adenovirus type 5, which they actually had
00:56:06 approved for use in the military. I'm not sure to what extent they've done it because it seems
00:56:09 they've gone in the other direction now and are looking just at an inactivated viral vaccine.
00:56:12 That seems to be their focus now. Yeah. I was going to say, do we have any data? I mean,
00:56:17 not that we would have any data from China necessarily, but we don't know how many people
00:56:20 received that outside of an actual clinical use and if there's been any other safety defects noted.
00:56:26 I mean, I have heard they have given it to tens of thousands of people, but what I haven't
00:56:29 heard is a result of the phase three trial. So I'd like to see whether or not it actually works
00:56:34 would be nice to see. And then the Russian, the Gamaleya Research Institute in Moscow
00:56:38 has also replication defective adenovirus vaccines and also is a two dose vaccine,
00:56:43 but the first dose is replication defective ad 5. The second dose is replication defective ad 26.
00:56:48 That's their vaccine. Vladimir Putin came out in the end of August and said,
00:56:52 we are going to now start giving this to our public, the Russian public. We have checked all the boxes,
00:56:57 which near as I could tell at the time was doing a small phase one trial. They hadn't even started
00:57:03 doing phase three trials yet. So I'm not sure what's going on in Russia. It's hard to know
00:57:06 what's going on. I know that I got a call from a Venezuelan reporter who said that that Russian
00:57:11 vaccine had been shipped to Venezuela for use. So I don't know what's going on out there,
00:57:14 but you really would like to wait for phase three trials to at least prove safety and efficacy at some
00:57:19 level before you start giving it to the general population.
00:57:22 The other big player here is Merck, although they're a step behind, right? They're mostly
00:57:26 phase one at this point. They have a candidate that has made it through phase one yet?
00:57:30 I've heard of two candidates. One is the replication competent vesicular stombatitis virus,
00:57:34 which although reproduces itself in your body, doesn't really cause disease. That's what they
00:57:37 use for their Ebola vaccine. That was Merck's Ebola vaccine. But they also apparently are interested
00:57:42 in using their measles vaccine virus as a vector for this as well. So I haven't seen any data yet.
00:57:48 But again, just summarizing where we are, we've got Moderna and Pfizer as the big guns on the mRNA
00:57:54 front. We've got Johnson and Johnson and then AstraZeneca with Oxford as the big guns on the
00:58:00 adenovirus slash viral vector front. Is that fair?
00:58:03 Yes.
00:58:04 As the leaders. Okay. So then the next sort of category is let's just give you the protein off
00:58:10 the virus itself. Let's just rip off a spike protein, give you a whole bunch of them.
00:58:16 And when your body sees those, it's not going to be threatened by them. I mean,
00:58:20 it's going to be threatened appropriately to make an immune response, but obviously the protein by
00:58:23 itself can't hurt you because it has no genetic material with which to take over your cells.
00:58:28 As a general rule, how does that strategy work when you think of other non-coronavirus
00:58:31 applications?
00:58:33 Right. So it's the strategy we use to make the hepatitis B vaccine with which we have had
00:58:37 experience since the 90s, early 90s. It's the strategy we use to make the human papillomavirus vaccine,
00:58:42 which has been on the market since mid 2000s, around 2006. It's a strategy we use to make one
00:58:47 of the influenza vaccines, so-called flu block, which has also been around for years. You have
00:58:52 the comfort at least of having a lot of commercial experience with that strategy. They're made using
00:58:56 recombinant DNA technology. So in the case, for example, of the hepatitis B vaccine or the human
00:59:01 papillomavirus vaccine, you take a yeast plasmid, which is just a small circular piece of DNA.
00:59:06 You clone into that the gene you're interested in, which as we've said now a million times on the
00:59:11 show, the coronavirus gene that codes for the coronavirus spike protein. You then sort of
00:59:15 transfect that into yeast cells, actually just common baker's yeast. And as the baker's yeast
00:59:20 reproduces itself, it also makes that protein, which you purify. In the case of flu block,
00:59:24 which looks like it's closer to the strategy that's being used by Sanofi GSK collaboration.
00:59:30 There, what you do is you take basically an insect virus, so-called bacalovirus. You clone into it again,
00:59:35 the gene that you're interested in, the coronavirus spike protein gene, and then you infect insect
00:59:39 cells. And then that protein actually forms rosettes as it's excreted from the cell. That's
00:59:44 where you make flu block, which I actually got this year as my influenza vaccine. And I'm still alive.
00:59:50 That's quadrivalent?
00:59:51 It's quadrivalent, yeah.
00:59:53 So you mentioned obviously Sanofi GSK. That's one of the big guns. They're not in phase three yet,
00:59:59 are they? They're going to start that next month?
01:00:01 Novavax is the other one that does purified protein, those two.
01:00:04 And Novavax is in phase three.
01:00:07 That's what I heard, yeah.
01:00:09 Yeah. But GSK Sanofi is next month for phase three.
01:00:13 Novavax was enrolling in November. They've started, and Sanofi was starting to roll in
01:00:18 December, so it should be soon.
01:00:20 Is there anything about this approach that tends to go really wrong? Me not being a virologist and
01:00:25 not knowing much about vaccines, of the three approaches we've discussed so far, I guess the
01:00:32 four, because we've already alluded to what the fourth strategy is, which is a live attenuated
01:00:36 virus. The protein-based delivery seems the most benign. Is that necessarily true?
01:00:42 I think that's fair. It's just a purified protein. Certainly we have a lot of history,
01:00:47 decades worth of history doing that approach successfully. If you look at Shingrix, which is, 0.99
01:00:52 again, a purified protein, it's just one of the proteins from varicella zoster virus,
01:00:56 that vaccine actually works better than the live attenuated viral vaccine, Zostavax.
01:01:01 And essentially it's replaced Zostavax.
01:01:04 We basically two years ago said, we're done. It's 100% switched to Shingrix now. Shingrix rather,
01:01:10 yeah.
01:01:10 Which is amazing. I mean, typically, historically, live attenuated viral vaccines always work better
01:01:15 than a single protein. The difference was the adjuvant. Shingrix has two powerful adjuvants.
01:01:20 Which we sort of separate, I think, by like six months or something?
01:01:23 No, no. They're all part of that vaccine. So one is monophosphorolipid A. The other is the
01:01:27 so-called QS21. That's all part of the varicella zoster virus. Glycoprotein E has these two
01:01:33 adjuvants that are all part of the vaccine. Oh, I see. But we give Shingrix in two... Is the
01:01:39 second one just a booster? You give two doses, right? It's the same thing. It's both contained
01:01:43 the same. Understood. Okay.
01:01:45 The adjuvant that's being used in the Novavax product is actually similar to the adjuvant in the
01:01:48 Shingrix product. So you wonder if you had to take a guess, maybe this would be the vaccine that
01:01:52 would be best for older people because that vaccine works remarkably well in older Shingrix 1.00
01:01:57 does. So this brings us to our fourth category then, which again, we've talked about, which is
01:02:01 these attenuated or live attenuated vaccines or inactivated vaccines. Now, this is something where
01:02:07 I think China has a number of products in the pipeline. I don't believe that there... Is there
01:02:12 a European or American counterpart in this space? Not that I know. It looks like all the inactivated
01:02:17 vaccines are coming out of China and they've done a lot with it. You could argue that could be the
01:02:21 first vaccine that is commercially available, if you will. The first one to have a clear phase three
01:02:28 trial. At least you should for my understanding for how much many people have been immunized in China
01:02:33 already. So let's talk a little bit about some of the other things that are going on here. We,
01:02:40 I think, I have to be honest, I'm very surprised. I think in March of this year, I did not think it was
01:02:47 plausible that there would be a vaccine on the market within a year. In fact, I probably would
01:02:52 have used the words impossible if you said to me in March, can there be a vaccine in a year? And by
01:02:59 the way, that wasn't just based on the financial thing. I mean, when I asked you that question
01:03:04 earlier, Paul, you alluded to how the government financially completely de-risked the operation.
01:03:10 And I won't diminish that in any way, shape or form. I just didn't think it was going to be from a 1.00
01:03:16 manufacturing standpoint possible enough to make enough GMP stuff at volume and actually put it
01:03:24 into clinical trials. I was like, there's no way. Like there's no way in 12 months we can get there.
01:03:29 Well, it turns out I was wrong. We're probably going to have vaccines on the market by January.
01:03:34 So let's start with a question about genetic drift. What do we know about how much the genome
01:03:41 of this thing is moving? So it's a single-stranded RNA virus. And like all single-stranded RNA viruses,
01:03:47 its replication isn't terribly faithful. Or said another way, it probably mutates to some extent
01:03:52 every time it reproduces itself. The critical question is, does it mutate in a manner that
01:03:57 causes a functional change? And by functional change, I mean more or less contagious or more
01:04:01 or less virulent. Or from the standpoint of the vaccine, does it mutate away from the vaccine so that
01:04:07 immunization or natural infection one year doesn't protect you the following year, which is the
01:04:11 influenza story. Influenza is also a single-stranded RNA virus, segmented RNA virus. But measles is a
01:04:17 single-stranded RNA virus too, so is mumps. And they have different genotypes, meaning that there is
01:04:21 drift, as you say, to cause there to be different strains, but never has measles really changed its
01:04:28 serotype. So the vaccine that worked in 1963 still works today. And so the question is, which of those,
01:04:34 is this virus going to be influenza-like, or is it going to be measles-like? I'm going to predict,
01:04:39 I'm happy to make a series of predictions, as long as you don't hold me to them. I would say that
01:04:44 I'd be surprised, although the virus continues to surprise, it is going to be more than a single
01:04:49 serotype disease. In other words, that a vaccine that works now could well work next year and the
01:04:53 year after that. Let's just make sure everyone understands what you said, because you said a lot
01:04:58 of interesting and important stuff there. Single-stranded RNA is, to put it mildly, a little sloppy.
01:05:04 That means every time this guy reproduces itself, it makes a little bit of a mistake. Sometimes those
01:05:11 mistakes don't mean anything. Sometimes they do. It's yet to be determined. There's two things,
01:05:16 at least, that matter with respect to the fidelity with which it can reproduce. One is, does it change
01:05:22 the properties of how the virus responds, either making it less toxic to us as humans or more toxic
01:05:28 or pathogenic to us as humans? I think it's definitely too early to say if that's happening one way or the
01:05:33 other. But the second property about its ability or inability to replicate itself perfectly is if it
01:05:40 makes so many changes in its replication cycle, it might look so different year after year after year
01:05:47 that our immune system, even if able to maintain robust immune cells that recognize the virus,
01:05:55 may functionally be duped by it because it looks so different each year. That's why we get flu shots
01:06:01 every year and we get MMR once, even though they're both single-stranded mRNA viruses.
01:06:06 You're basically saying if you had to guess, this is going to be between them. So it's not going to
01:06:12 be changing so dramatically every year that we would need to go through this exercise annually. Is that
01:06:18 what you're saying?
01:06:19 Yeah, I'm going to predict actually it's going to be more measles-like, that it's not going to drift
01:06:23 in a manner that means that the vaccine no longer works. That'll be my prediction,
01:06:27 but I have been wrong about this virus before. The good news is, I mean, I think we're getting
01:06:33 to about a year on this thing. And I think the virus we're seeing today does not look meaningfully
01:06:38 different from that, which was identified in January. So hopefully that speaks in your favor.
01:06:43 Do we have a sense of how these vaccines are working at the real molecular level? Obviously,
01:06:49 we love to look at immunoglobulins as a proxy for immune response. So, hey, this generated IgG and IgM,
01:06:57 but there's been a lot of talk about the solubility of those things. And are those immunoglobulins
01:07:03 actually active? Just because they're present, do they actually have the binding capacity to the
01:07:08 virus to actually eradicate it? Of course, there's been a lot of talk about T-cells and how some people
01:07:14 might be getting a less aggressive version of COVID because perhaps they had some T-cells that
01:07:22 recognized a separate coronavirus that they may have had six months sooner. What's your thinking,
01:07:29 or what's the latest thinking on those hypotheses and ideas?
01:07:32 This virus, SARS-CoV-2, is essentially a bat coronavirus that just reared its head in Wuhan
01:07:38 in the middle of November of last year, and now has swept across the world and made its debut in the
01:07:45 human population. We are infected with human coronaviruses all the time. I mean,
01:07:49 there are four strains of human coronaviruses that circulate. They were first identified in
01:07:53 the early 1960s. They're no doubt circulating well before that. They cause respiratory infections,
01:07:58 meaning congestion, cough, runny nose, occasionally more severe disease, pneumonia. They account for
01:08:03 probably about 15 to 20% of the diseases that we see in our emergency department or in our hospital
01:08:09 every year. And that's pretty much invariant. The question is, because the human coronaviruses do share
01:08:15 some similarity to this bat coronavirus, which is recognized by what's called helper T-cells,
01:08:20 does your previous experience with human coronavirus, which we pretty much all had,
01:08:24 mean something to us in terms of protecting us against this virus? I don't think so,
01:08:28 is my sense of it. In terms of what works, I mean, I guess I'm very simplistic on this based on my
01:08:33 experiences with rotavirus. I think the trick is keeping the virus from binding to cells. It's really
01:08:38 the way the measles vaccine works, the way the mumps vaccine works, the way the rubella vaccine works,
01:08:42 the way the varicella chickenpox vaccine works. If you can prevent the virus from binding to cells,
01:08:46 you can prevent the virus from entering cells. So when you make antibodies, are those antibodies
01:08:50 directed against the so-called part of the spike protein, the receptor binding domain of the spike
01:08:55 protein that is neutralizing the virus? You want to neutralize the virus. You don't want to just
01:09:00 bind to the virus. You want to neutralize it so it can't attach to cells. And that's the business end
01:09:05 of the SARS-CoV-2 spike protein is that so-called receptor binding domain. So that's the question.
01:09:11 And the other question I think that people are worried about is that antibodies can fade
01:09:14 over time, even if they're natural infection. So what does that mean for a vaccine, if antibodies
01:09:18 fade? And this is a little complicated, but when you're inoculated with a vaccine or when you're
01:09:23 naturally infected with a virus, it's not just that you make antibodies, you induce immunological
01:09:27 memory. So you have memory B cells, the kind of cells that make antibodies, or memory T cells.
01:09:32 And so they're sort of like the base of the iceberg with the antibodies being the tip of the iceberg.
01:09:36 Do they matter? They do matter, especially for longer incubation period diseases. So for
01:09:42 really short incubation period diseases like rotavirus, meaning the time from when you're
01:09:46 infected to when you get sick, rotavirus, influenza, respiratory system virus, those have short incubation
01:09:52 periods. This is sort of a medium length incubation period, around six, seven days. Measles is much
01:09:57 longer, sort of 10 to 14 days. For longer incubation period diseases, there's enough time then
01:10:03 for activation and differentiation of memory cells to become, in the case of B cells,
01:10:08 antibody secreting cells. So it still would work. I think that's where we're going to be. So I think
01:10:12 memory is important. So when people talk to me about how nervous they are that antibodies are fading,
01:10:17 I'm not sure you should be nervous about it yet. Let's wait to see what happens as we move forward
01:10:21 with these vaccines. Yeah, I think that's a great point, Paul. And I think there's really two points
01:10:25 you made there that speak to that. The first is, it's not antibodies that probably matter. It's
01:10:30 neutralizing antibodies. And frankly, we don't have commercial tests for that. So I don't know how
01:10:35 much it matters that your serology test that's measuring IgG and IgM levels over time is changing
01:10:41 when that's not actually, or certainly not necessarily the thing that we care about. We
01:10:46 care about neutralizing antibodies, not antibodies. Your second point is just spot on, which is unless
01:10:53 somebody is sampling bone marrow, looking for B cells that have memory, again, maybe this doesn't
01:10:59 matter. And we at least, if there's one upside to having the long incubation period, which has
01:11:05 allowed this silly virus to replicate like crazy and spread around the world, at least it's that the
01:11:10 immune system gets some chance to rev up against it. I guess I always think of it that way, like 0.96
01:11:16 biology usually takes something and gives something, right? It's like, if this thing had no time between
01:11:22 when you were infected and when you got sick, you'd probably get sicker because you wouldn't have any of
01:11:27 that memory response, but at least it would have been contained or sort of have the opposite
01:11:31 problem. That's a glass half full way to look at this, I suppose.
01:11:34 Let me offer one thing just as hopeful because as you get older, you get sort of grimmer, but I'm
01:11:38 trying to offer some hopeful thing. But it appears that, especially in men, there were two papers in
01:11:43 science that showed that when you're infected with this virus, SARS-CoV-2, that you can actually make
01:11:48 antibodies directed against interferon, which is a protein that your body's immune system makes to help
01:11:53 fight viruses. That's where the name comes from. It interferes with the ability of virus to infect
01:11:57 cells. And the thinking is that that may be one reason why men are more likely to suffer and die
01:12:02 from this disease than others. This offers hope for the fact that a vaccine may be better than natural
01:12:08 infection, because it's unlikely that a vaccine would do that. There certainly are examples of
01:12:12 vaccines that are better than natural infection. This may be one of them. There's some reasons for hope
01:12:16 here. Do you see any differences in male versus female on vaccine, or do you think no? I mean,
01:12:21 there's nothing that has been published to date that has suggested a gender disparity between this?
01:12:27 No. As a general, men tend to die and boys tend to die at a greater frequency than girls for most
01:12:33 infectious disease. We are the weaker sex, or as Murphy Brown used to say, that silly little Y chromosome. 0.97
01:12:39 Do you think that's a response to a greater cytokine response, or what do you think accounts for that 0.55
01:12:45 difference? I'm not sure. Even when we age match and we match for morbidity, we don't know why?
01:12:51 We're the weaker sex. Let's admit it.
01:12:54 A bit off topic, blood type. There was a lot of talk earlier about anti-A antibodies potentially
01:13:01 being a little bit protective. Do we have more data on that?
01:13:03 I hadn't seen it. Having type O blood would be some level protective, because you can make
01:13:08 antibodies to A or B types. I think I would still put that in the hypothesis unproven category.
01:13:13 Okay. Do we have any data on the robustness of the immunologic response, at least based on phase
01:13:23 two metrics in different demographics, starting with young versus old, obese versus non-obese,
01:13:30 or some other metric where it's going to matter? Because at some level, there's going to need to be
01:13:35 some rationing of this, right? It's not like vaccine gets approved on Wednesday, and on Thursday,
01:13:41 300 million copies of the vaccine show up to everybody's doctor. So whether we like it or not,
01:13:47 there's a slow roll and a partition to how this happens. What do we know about it in that sense,
01:13:52 in terms of how people are responding to it, and who's most vulnerable, and who should be getting it?
01:13:55 Both the National Academy of Medicine and the Advisory Committee for Immunization Practices at the CDC
01:13:59 have come up with their first-tier group. But it's huge. The first-tier group includes
01:14:04 healthcare workers. It also includes other essential personnel, like people who work in
01:14:09 mass transportation, or grocery stores, or pharmacies, or work in law enforcement, or sort
01:14:14 of water purification. That includes people over 65, who, when they get infected, are more likely to die.
01:14:20 And it includes people with certain high-risk medical conditions, like obesity, which is probably
01:14:25 30% of the American population, and diabetes, and chronic obstructive pulmonary disease, et cetera.
01:14:30 If you add that all up, it adds up to about 150 million adults, which is half the adult population
01:14:37 in the United States, who are going to require a two-dose vaccine, which is already 300 million
01:14:42 doses. And that's not going to happen immediately. So how do you partition that? I don't know. I mean,
01:14:47 I'm on this Commonwealth of Pennsylvania group that tries to make decisions like that. I'm on our
01:14:52 hospital group to try and make decisions like that. I think it's going to be a real learning curve
01:14:57 that's associated with how this rolls out. What are we prepared to do about that? Is this
01:15:01 going to produce social unrest? It sounds crazy, but have we ever experienced something like this
01:15:07 from a healthcare delivery standpoint? No. I mean, this is a virus that's killed 230,000
01:15:11 people. So this may be sort of like the end of the movie Contagion, where people are like breaking
01:15:15 down doors trying to get a vaccine, where vaccines were the hero of that story. I think there is going
01:15:20 to have to, at some level, be a rationing in terms of who gets what and how it's going to be done. And
01:15:26 I don't know. It's really complicated, right? So Moderna is basically the NIH, Pfizer, J&J,
01:15:34 AstraZeneca, and Oxford. I mean, these companies have presumably never been in a situation to have to
01:15:40 say, here's where this shipment goes to this pharmacy versus that pharmacy, or this city versus
01:15:46 that city. I mean, not to dwell too long on a seemingly strange question, but we're not that
01:15:51 far from when this is going to happen. We're only a couple months away from that, potentially.
01:15:56 So it's the Department of Defense that's going to take the lead at Operation Warp Speed for
01:16:00 determining where these vaccines get distributed, but they'll be distributed to the states. And then
01:16:05 the states, I think, will decide how to sort of apportion that, is my sense of it. The CDC initially
01:16:10 had sort of four states in one city, which was Philadelphia, actually, to try and do kind of this test
01:16:15 program for how it would be distributed. Now, Pfizer is not an Operation Warp Speed vaccine,
01:16:20 so they may have a different distribution strategy. But I think you're right. It's going to be a real
01:16:26 challenge, plus it's a two-dose vaccine, plus it means you have to get people back for the second
01:16:30 dose, and some of these vaccines are going to be stored at minus 70. It's going to be really a
01:16:34 challenge to see how we get it out there. I mean, we had one issue in our hospital, which was easily
01:16:38 resolved, which was, should we mandate the vaccine for hospital workers? No. One, for the practical
01:16:44 reason that we probably won't have a lot of vaccine. And two, I think that with a novel
01:16:47 vaccine strategy like messenger RNA or these replication-defective viruses, I don't think
01:16:52 you really can fairly mandate that. I think you really should wait till it's out there a little
01:16:56 more. There's going to be plenty of people who are going to be perfectly willing to take these
01:16:58 vaccines, and then we'll have a few million doses out there, and we'll have a better sense of
01:17:03 things. Maurice Hilleman, who I consider the father of modern vaccines, having either done the primary
01:17:07 research or development on nine of the 14 that we use, said it best. He said, quote,
01:17:12 I never breathe a sigh of relief until the first three million doses are out there.
01:17:16 So we'll see.
01:17:18 Personal question, would you take the vaccine right now?
01:17:21 Not till I see the data. The good news, I'm on the FDA vaccine advisory board, so I will see the
01:17:25 data. And if I feel confident that the safety issues look good, issues look good for people my age. I
01:17:31 mean, I'm over 65. I want to feel I'm adequately represented in these trials.
01:17:36 At a sample size of 30,000, of which, let's say, a third of them are over 65,
01:17:42 would 10,000 people over 65 having no adverse effects in three months make you feel comfortable
01:17:49 enough to take it? I think it would, yes.
01:17:52 Okay. And I'm going to point something else out to the listener who can't see you.
01:17:56 You at least look to my eye as a very healthy 65-year-old. You look like you're about 55.
01:18:02 You're not overweight. I assume you don't have diabetes. You look like a model of health.
01:18:06 So are you really that high risk aside from your age? And if so, why are you taking it?
01:18:12 Just my age.
01:18:12 Okay. So do you still believe that age by itself is enough of a predictor of morbidity beyond
01:18:20 the obvious comorbidities that tend to track with age that presumably, at least, let's just assume
01:18:26 you don't have them. Not that I'm asking you to disclose any medical things, but you're about as
01:18:29 healthy a 65-year-old as there's going to be out there.
01:18:32 I would take it not because I necessarily think I'm going to die from this virus. It's because I
01:18:36 think that way I feel between taking a vaccine and wearing a mask and social distancing, I
01:18:42 dramatically decrease having to suffer this virus. I mean, the virus, yes, it's a killer. And yes,
01:18:47 it can cause pneumonia, which can kill you. What scares me the most about this virus is that
01:18:51 it can cause vasculitis. I mean, who would have predicted that? It causes this multi-system
01:18:56 inflammatory disease of children. And it can affect, it can cause heart attacks, it can cause strokes,
01:19:01 it can cause liver or kidney disease because it causes vasculitis. So why does it cause vasculitis?
01:19:06 It doesn't really enter the bloodstream. Fewer than 1% of people infected with this virus have
01:19:10 so-called viremia. So it induces your immune response to damage endothelial cells that line
01:19:15 blood vessels. And because every organ in your body has a blood supply, every organ can be affected.
01:19:19 I mean, the so-called long haulers, at least in part, are probably determined by a vasculitis,
01:19:25 maybe even at low level. That's what scares me about this. This is not a virus that just gets in,
01:19:29 kills you and gets out, or gets in, makes you sick and gets out. There are longer term effects
01:19:33 with this virus and it should be taken seriously. I mean, I think when the administration occasionally
01:19:37 says things like, you need to embrace this virus or live with kind of, you know, this kind of notion
01:19:42 that the virus would eliminate itself by population-induced immunity, which has never happened
01:19:47 for a virus before. I think they sort of ignore the fact about the long-term issues of this particular
01:19:51 virus, but this isn't flu. I think of all the sort of lingering tail events of this virus,
01:19:57 the one that probably concerns me the most is some of the cardiomyopathy that we're seeing
01:20:02 persist in, especially in young people. On a personal level, I've just had to strike a balance
01:20:06 between living my life, but still trying not to be reckless. And to me, that's a really bad outcome,
01:20:13 right? Is the probability that I'm going to die from this low? Yeah, it's staggeringly low,
01:20:19 but there's some risk that I can't quantify of cardiomyopathy or some lingering respiratory
01:20:26 thing that never fully resolves that impairs quality of life. I guess the real question is just
01:20:31 the trade-off between how efficacious in the real world, and therefore I guess effective is the better
01:20:38 word, do I think this vaccine is relative to what other risks? I think what I'm hearing from you that
01:20:43 I actually find heartening is at least using history as a guide within a few months of this vaccine
01:20:51 coming out and entering the real world, which we can think of as phase four. We'll think of that as
01:20:56 post-market surveillance phase four. We're going to have a pretty good sense of it. And most of us
01:21:03 listening to this podcast are not going to be the guys getting it on day one, just due to the simple
01:21:08 logistics of it. Like I'm not going to be in the first million doses of this vaccine. You aren't
01:21:13 going to be in the first million doses of this vaccine. There are people, frankly, who are at much
01:21:18 higher risk that deserve to be there. And I guess we'll have a better sense of it. But I think that
01:21:23 this discussion for me, Paul, is also interesting because it really frames the four different types
01:21:28 of strategies that one can go about doing this, who the players are and what the risks are
01:21:34 potentially in each of them and why maybe a Sanofi product ultimately might end up being safer than,
01:21:39 say, a J&J product. The devil's in the details. The only thing that's going to matter is, hey,
01:21:44 how do these things look six months after they've been on the market? The other thing I wanted to ask
01:21:49 you about is, is there ever going to be a time when we're going to be immunizing children against this
01:21:55 virus? I mean, what do we know today about kids getting infected by this? We know that children
01:22:00 are less likely to be infected and when they're infected are less severely infected. I mean,
01:22:05 of the people less than 21 years of age in the United States, make up about 26% of the population,
01:22:11 yet they account for 0.08% of the deaths. That said, about 120, at least the last morbidity
01:22:18 mortality week, the report showed that about 120 children had died from COVID-19. That's not very
01:22:23 different than the number of children that died from influenza last year, which was around 140.
01:22:27 That's what it usually is, around anywhere 140, 150, 160 in that area. So it's no more or less fatal
01:22:34 than influenza for children. Two, it can cause long-term problems in children with the so-called
01:22:40 MISC disease of children. So I think there is a compelling desire to make a vaccine for children.
01:22:47 So how to do that? Now, all the trials initially were done in people over 18. So we weren't studying
01:22:52 children initially. Now, recently Pfizer sort of dropped the age to 16 and then they've dropped the age to 12.
01:22:56 So they're starting to look at younger people. So the question is then, what happens, and this applies
01:23:01 broadly, what happens if a vaccine is approved through EUA? Pfizer has already said, if that happens for
01:23:06 them, they're going to start to immunize their control group, which means now you lose information
01:23:11 about safety and efficacy moving forward. Why is that, Paul? Is that basically as a thank you to the
01:23:16 control group and basically a crossover? Look at what that does. From a scientific standpoint, you just
01:23:22 lost your test case, but what is the rationale for doing that?
01:23:25 I think it's a thank you for being, and that may have been part of the deal when they signed up for
01:23:29 the trial. I don't know. Yeah, got it. Okay. To get to the children, this could be done in one of
01:23:34 two ways. It could be done as a placebo-controlled trial, it's the same way we do adults, or it could
01:23:39 be done as immunobridging studies, meaning that you actually find out there is an immunological
01:23:42 correlate of protection in adults, that it is a certain level of neutralizing antibodies that's
01:23:47 evoked. And then if you give to children a certain dose, that you find that you get that level of
01:23:51 neutralizing antibodies, and so then you just move forward. And then you look retrospectively,
01:23:55 because not all children will be inoculated at the moment that you start inoculating children,
01:23:59 you can see whether or not it's... It's basically the same way that it worked with the Ebola vaccine.
01:24:04 I mean, that wasn't a prospective placebo-controlled trial in West Africa. People just started getting
01:24:08 vaccine, and because not everybody got it at once, you could get a sense of effectiveness
01:24:11 by knowing who got the vaccine and who didn't. So that may be it. When we had the FDA vaccine
01:24:16 advisory committee meeting on October 22nd, the FDA was very clear about this, that when you approve
01:24:21 something under emergency use authorization, which is the same sort of permission you would give to
01:24:25 an investigation of a new drug, you were really under no ethical obligation to vaccinate a placebo
01:24:30 group. You aren't. And nor are you under an ethical obligation to no longer do placebo-controlled
01:24:35 trials. Now, I'm not sure how that's going to play out. I mean, you can see, for example, if somebody's
01:24:39 70 years old, they see that this vaccine works, and they were in the placebo group, they can say,
01:24:44 I want this vaccine. So what the FDA has argued for is why not just make it an expanded access
01:24:49 issue or extended access, which is what used to be called compassionate use access, but do it that
01:24:55 way. And I think that may be the way this plays out. I don't think I'm making a bold prediction by
01:24:59 saying I think the first vaccines may not be the last best vaccines, but you have to know that you
01:25:03 have the last best vaccines. You have to know that down the line, there may be a vaccine that's 90%
01:25:07 effective. And you can't know that unless you do it as a placebo trial. And again, if you're going to do it
01:25:12 with the other vaccine as a trial, the thing that would require a huge trial, I mean, really,
01:25:18 you'd be hard to prove it. You actually wrote an interesting paper this summer about the role of
01:25:24 fever in fighting infection in children. I was really surprised at the results. And I got to tell
01:25:32 you, it's kind of changing the way I think about how much Tylenol I kick around the house. You want to
01:25:38 talk a little bit about what that paper showed while we're on the topic of kids?
01:25:41 Right. You actually wrote a book called Overkill When Modern Medicine Goes Too Far. And that's the
01:25:45 first chapter sort of in defense of fever, that treating fever can prolong or worsen illnesses. And
01:25:50 the reason is, is that pretty much everything that walks, crawls, flies, or swims on the planet can make
01:25:56 fever. Why do we do that? We do it because our immune system actually works better at a higher
01:26:01 temperature. It's not because viruses or bacteria die more quickly at a higher temperature. It's because
01:26:06 your immune system works better. B cells make antibodies more efficiently. Neutrophils are
01:26:10 white blood cells that form pus can travel to areas where bacteria are and kill bacteria more
01:26:15 efficiently. So if that's true, if your immune system works better at a higher temperature, then
01:26:19 are there studies done showing that people who are given anti-fever medicines like Tylenol or
01:26:25 ibuprofen, do they do worse? And the answer is redundantly, yes. And in the world of vaccines,
01:26:31 when people choose to treat fever with anti-fever medicines when they've gotten a vaccine, you have
01:26:36 a lesser immune response. I mean, over and over again, this has been shown, yet we just can't help
01:26:41 ourselves because we want people to feel better or we want ourselves to feel better. But know this,
01:26:45 that you are hurting one part of your immune system when you do that.
01:26:49 Is there a danger at some point, Paul, of kids having fevers when the temperatures get too high? I mean,
01:26:54 I always feel like that's the one thing that scared the hell out of medical students or residents,
01:27:00 was you'd see those kids with febrile seizures. And so you have that image in the back of your mind
01:27:04 of that kid in the ER that's seizing. And then God forbid, they go on to have some neurologic
01:27:09 consequence. And so you're sort of hardwired to think, well, God forbid, I'm ever going to let a
01:27:13 child have a fever again. What's the risk of that? And at what temperature is that something that a
01:27:18 parent needs to be aware of? So so-called febrile seizures are benign. I mean, my daughter actually
01:27:23 had a febrile seizure. They're generally short-lived. They don't have long-lasting sequelae. And it's not
01:27:27 the height of the temperature. It's the rapid rise in temperature that causes that. So it's not
01:27:31 height. And for the most part, I'm going to say for the most part, I think physiological fevers
01:27:34 don't cause harm. Your body is not interested in hurting you in that way. Now, environmental
01:27:39 fevers can. Heat stroke. I mean, the laborer or the athlete or the soldier who's out there in heavy
01:27:44 gear and on a hot day and is not able to dissipate heat through sweating, they can suffer strokes.
01:27:49 I mean, it's, you know, you can die from heat strokes. In fact, about 600 people die from heat
01:27:53 strokes every year. So environmental fevers can do that, but not physiological fevers.
01:27:57 So again, I think you jump with a net. It's just very hard to watch this. A case actually
01:28:01 near a hospital of a boy, a soccer player was hit on the hip. He had a clot in a vein,
01:28:06 so-called thrombosis. And then that got infected, so-called thrombophlebitis, with staph, the MRSA,
01:28:12 the sort of hard to treat staph. Traveled to his brain and caused abscesses. It traveled to his
01:28:16 lungs and caused abscesses. It traveled to his bone and joint and caused abscesses. We were
01:28:19 treating with an antibiotic vancomycin that should have treated that, but he was continually
01:28:23 positive, had blood cultures that continued to show he was shedding bacteria. And every day,
01:28:28 every two hours, we were rotating, you know, either Tylenol or ibuprofen. Finally, I met with a boy,
01:28:33 I met with the parents, I met with a nurse, and I said, stop treating his fever. Just give his body
01:28:37 a chance to have every part of his immune system working for him. And then within really about a
01:28:42 day and a half, there's no longer shedding bacteria. That may have been a complete coincidence. It's not a
01:28:46 proof in any sense, but you couldn't convince the parents of that. They thought we were geniuses by
01:28:50 doing it that way. Give his immune system a chance to work as good as it can. Why cripple his
01:28:55 neutrophils ability to ingest and kill bacteria by giving him anti-fever medicines? We think we're
01:29:00 helping. Is there any scenario then, Paul, in which, I mean, that's a pretty compelling case. Is there
01:29:04 any scenario under which you would recommend taking something like Tylenol? I think if somebody cannot
01:29:09 handle the metabolic strain of increase of, I mean, because you increase your basal metabolic rate
01:29:14 a certain percentage for every degree centigrade increase in your fever, I think it's like 12% increase in
01:29:19 BMI for every degree centigrade. But so if you have chronic lung disease, chronic heart disease,
01:29:24 metabolic disease that makes you unable to handle that rise in temperature, sure. I think that's
01:29:28 the reason. But otherwise, no. Wow. So suffer it out, huh? Yeah. And that's that boy. I love this
01:29:34 boy. He was a teenager, a young teenager. And he was just brave. He was, okay, fine. Everybody was in.
01:29:39 We were going to do this thing. And nurses were in. We were going to ride it out. And then
01:29:44 he did better. All right. Last thing I want to say on vaccines, just to kind of close the loop on this,
01:29:49 are there viruses besides the obvious, like HIV and even hep C, I guess, where just vaccinating
01:29:56 them is either impossible or outright dangerous? I mean, there was something about RSV, which we've
01:30:01 talked a little bit about that, I mean, RSV is really common, but there's no vaccine to RSV.
01:30:07 Is that just that it's not cost-effective or was there sort of a more technical issue with it or a
01:30:12 risk associated with creating vaccine towards it? The more technical issue of creating a vaccine,
01:30:17 there were two events that occurred in the 1960s. One was with RSV where Bob Chanik, head of the
01:30:22 Laboratory of Infectious Diseases at NIH, wanted to make an RSV vaccine. This is a virus that causes
01:30:28 pneumonia. It causes about 5,000 deaths every year in the United States, primarily in young children,
01:30:32 especially premature children, babies. So let's make an RSV vaccine. He took the virus, grew it up,
01:30:38 and activated it with formaldehyde, just the same way that Jonas Salk made his polio vaccine,
01:30:42 and then gave it to babies. And what he found was that children who got that vaccine did worse.
01:30:46 They were more likely, when they were then exposed to the natural virus, they were more likely to
01:30:50 develop pneumonia, more likely to be hospitalized. In the case of two children, more likely to die
01:30:54 than children who never got that vaccine. Same thing happened with the measles vaccine in 1963.
01:30:59 Take the virus, grow it up, purify it, kill it with formaldehyde. That too caused children to have
01:31:04 an aberrant immune response directed against that measles virus that causes atypical pneumonia. So they
01:31:10 were more likely to get pneumonia than children who were never vaccinated. That was ultimately taken
01:31:14 off the market. The reason that may be relevant to today, to SARS-CoV-2 today, is that both of those
01:31:19 viruses, respiratory syncytial virus and measles, have a fusion protein. That's how it attaches to
01:31:25 cells, it fuses to cells. So does SARS-CoV-2. It has a fusion protein. So people are always a little
01:31:29 nervous about an inactivated vaccine. And it's because you sort of change the confirmation of that
01:31:34 protein, that SARS-CoV-2 protein, so it didn't really look like it looked on the natural virus. So that's
01:31:39 always in the back of people's minds with fusion proteins. So you asked me earlier what sort of
01:31:43 safety things I'm worried about. That actually is one of the safety things. And that would be
01:31:47 more of a concern, I'm guessing, with the live attenuated virus as opposed to the other three
01:31:53 classes, or would you still worry about that in the mRNA and the viral vector viruses?
01:31:59 I worry about it with all of them. You worry that the confirmation as made under these conditions,
01:32:03 mRNA or DNA or replication defective virus, or a whole kill virus, or recombinant DNA generated,
01:32:09 proteins, that it's different. It's critically different than the way it sits on the virus
01:32:13 surface.
01:32:13 Paul, this is an unbelievably fascinating discussion. I'm glad I waited on this. You and I were going to
01:32:20 speak a couple of months ago. Obviously, for so long, I've wanted to have a deep dive on the vaccine
01:32:26 stuff. But I feel like this was the right time to do it, at least to be able to speak about it with
01:32:30 more clarity and to really be able to say, look, by the time someone's hearing this, we're really on
01:32:35 the cusp of these vaccines being out there in early 21. But it's not a switch. It's not a binary
01:32:40 thing. It's not like we're going from no vaccines to everybody gets vaccines, and there's perfect
01:32:45 information, and there's no risk. This is analog in delivery, analog in risk. I mean, it's analog in
01:32:54 pretty much everything other than approval. Yeah, I think we're going to learn a lot. Thanks for asking
01:32:58 me. I enjoy this, really. I don't think I've ever done a podcast this long, but it was definitely
01:33:02 fun. And in fact, I thought you said two hours. I thought, oh my God, two hours. I'm going to live
01:33:06 through this. It really flew. It was just surprising. Well, I appreciate your time and
01:33:12 your willingness to sit down for so long, Paul. My pleasure. Thanks for listening.
01:33:16 Thank you for listening to this week's episode of The Drive. If you're interested in diving deeper
01:33:20 into any topics we discuss, we've created a membership program that allows us to bring you
01:33:24 more in-depth, exclusive content without relying on paid ads. It's our goal to ensure members get back
01:33:30 much more than the price of the subscription. Now, to that end, membership benefits include
01:33:35 a bunch of things. One, totally kick-ass, comprehensive podcast show notes that detail
01:33:40 every topic, paper, person, thing we discuss on each episode. The word on the street is nobody's
01:33:45 show notes rival these. Monthly AMA episodes or Ask Me Anything episodes, hearing these episodes
01:33:51 completely. Access to our private podcast feed that allows you to hear everything without having to
01:33:57 listen to spiels like this. The Qualies, which are a super short podcast that we release every
01:34:02 Tuesday through Friday, highlighting the best questions, topics, and tactics discussed on
01:34:06 previous episodes of The Drive. This is a great way to catch up on previous episodes without having
01:34:12 to go back and necessarily listen to everyone. Steep discounts on products that I believe in,
01:34:17 but for which I'm not getting paid to endorse. And a whole bunch of other benefits that we continue
01:34:22 to trickle in as time goes on. If you want to learn more and access these member-only benefits,
01:34:27 you can head over to peteratiamd.com forward slash subscribe. You can find me on Twitter,
01:34:33 Instagram, and Facebook, all with the ID, peteratiamd. You can also leave us a review on
01:34:39 Apple Podcasts or whatever podcast player you listen on. This podcast is for general informational
01:34:44 purposes only and does not constitute the practice of medicine, nursing, or other professional
01:34:49 healthcare services, including the giving of medical advice. No doctor-patient relationship
01:34:55 is formed. The use of this information and the materials linked to this podcast is at the user's
01:35:00 own risk. The content on this podcast is not intended to be a substitute for professional
01:35:05 medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice
01:35:13 from any medical condition they have, and they should seek the assistance of their healthcare
01:35:17 professionals for any such conditions. Finally, I take conflicts of interest very seriously. For all
01:35:24 of my disclosures and the companies I invest in or advise, please visit peteratiamd.com forward slash
01:35:31 about where I keep an up-to-date and active list of such companies.
01:35:47 Thank you so much for joining us.
01:36:02 Thank you.
01:36:04 Thank you.